Hansa Biopharma AB (publ) (STO: HNSA)

Market Cap	2.64B
Revenue (ttm)	189.39M
Net Income (ttm)	-654.78M
Shares Out	67.81M
EPS (ttm)	-11.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	482,987
Open	37.18
Previous Close	36.64
Day's Range	34.12 - 39.16
52-Week Range	22.88 - 57.30
Beta	1.44
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 6, 2025

About Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 168
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: HNSA

Financial Performance

In 2023, Hansa Biopharma AB's revenue was 134.09 million, a decrease of -13.22% compared to the previous year's 154.53 million. Losses were -831.72 million, 36.1% more than in 2022.